跳至主要内容
临床试验/NCT03145103
NCT03145103已完成不适用

Clinical Safety and Efficacy of Hydrophilic Acrylic Intraocular Lenses - Retro Prospective Study

Carl Zeiss Meditec AG2 个研究点 分布在 1 个国家目标入组 282 人开始时间: 2017年8月7日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
282
试验地点
2
主要终点
Visual acuity

研究概览

简要总结

Clinical safety and efficacy of CT ASPHINA 409 IOLs after implantation

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient informed of the consequences and constraints of the protocol and who has given his/her written informed consent;
  • Patients of any gender
  • Assured follow-up examinations
  • Biometry measurement preferably compatible with the IOLMaster evaluation;
  • IOL implanted into the capsular bag with IOL model CT ASPHINA 409MP (UVE material) in one eye with at least 12 months follow up at the time of the postop visit
  • Patients who had uncomplicated (no peroperative complication) aged-related cataract surgery in a healthy eye (beside clinically significant cataract)

排除标准

  • BCVA not available preoperatively or better than 0.3 logMAR pre-op
  • Patients unable to meet the limitations of the protocol or likely of non-cooperation during the trial
  • Patients whose freedom is impaired by administrative or legal order
  • Concurrent participation in another drug or device investigation -

研究组 & 干预措施

409M

Experimental

CT ASPHINA 409M IOL

干预措施: CT ASPHINA 409 (Device)

结局指标

主要结局

Visual acuity

时间窗: 12 to 18 months after surgery

Monocular best corrected distance visual acuity

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验